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1. Introduction 
Kininogen is a heterogenous plasma glycoprotein 
and source of the vasoactive kinin peptides. Two main 
forms of human kininogen are well known, the high 
molecular mass (Wr 120 000) and the low molecular 
mass (IiWr 50 000-78 000) kininogens [l-3]. I-I$ 
kininogen functions as a cofactor in the contact acti- 
vation of F XIIa and F XIa [4]. The cascade reactions 
leading to the formation of fibrin in the intrinsic path- 
way of blood coagulation also involve activation of 
kallikrein (EC 3.4.2 1.8) in an amplifying feedback 
mechanism between prekallikrein and F XII. A small 
amount of surface-bound F XII has been shown to 
catalyze the formation of low levels of kallikrein. 
Whether these reactions shown to occur in vitro when 
blood plasma comes into contact with glass occur 
under physiological conditions is not yet known [5,6]. 
The two molecular forms differ primarily by the 
structure of their respective light chain, which in the 
HMr kininogen contains a histidine-rich fragment 
responsible for the coagulation effect and covalently 
bound to the heavy chain through the vasoactive pep- 
tide segment (bradykinin). However, UM, is present 
in normal human plasma in a higher concentration 
while HMr kininogen constitutes an average 15% of 
the total kininogen content [7,8]. A relationship 
between the two molecular forms has been suggested 
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[7]. A common nominator appears to be the shared 
antigenic determinants in the heavy chains [ 1,9,10]. 
In studies so far I&fr and HMr kininogens have 
been characterized by content of active kinin segment 
or coagulating activity. Here, we describe a radioim- 
munoassay method for the identification after separa- 
tion on SDS-PAGE of various molecular forms of 
HMr kininogen produced by activation of intrinsic 
kallikrein, UM, kininogen, a kininogen from Cohn’s 
fraction IV and the respective heavy chains. 
2. Materials and methods 
2 .l . Preparation of kininogen 
WMr-BKG (-105 000-85 OOOMr by SDS-PAGE) 
was prepared from 400 ml normal human blood bank 
plasma, diluted 1: 1.6, according to the procedures in 
[3] using 0.1 M Tris-HCl buffer (pH 8.0) containing 
3 mM EDTA and PMSF (Sigma Chemical Co.) and 
0.04% PBR. The 0.35 M NaCl eluted fraction pool was 
dialyzed, precipitated at 50% ammonium sulphate sat- 
uration and chromatographed on SP-Sephadex C-50 
[2]. LMr-BKG (-60 000 Mr) was prepared as in [8]. 
Immunoreactive kininogen (BKG-C, single polypep- 
tide chain, -60 000 Mr) was purified from freshly pre- 
cipitated Cohn’s plasma fraction IV [lo]. The purity, 
amounts, homogeneity and approximate Mr-values 
were estimated by double diffusion, single radial immu- 
nodiffusion analyses [ 11-l 31 and SDS-PAGE [ 141. 
2.2. SDS-PAGE 
BKG samples were run by SDS-PAGE (8% slab 
gel) native and after reduction with 5% mercaptoetha- 
no1 (Fluka AG) [ 141. The protein was recovered from 
the sliced (3 mm) polyacrylamide (BDH Chemicals 
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Ltd.) gel strips by elution with 0.1 ml TES buffer 
(pH 7.35), 0.15 M NaCl [15], or with 0.2 ml 0.15 M 
NaCl and shaking for 18 h (22’C). Control runs with 
the protein samples were run in parallel and stained 
with Serva blue R. 
2.3. Preparation of antisera 
Monospecific antisera against the immunologically 
pure antigens LM,-BKG and BKG-C were raised in 
rabbits [ 161. The titers were 0.3 mg/ml and 1 .O mg/ml, 
respectively [ 171. 
2.4. Determination of kallikrein 
Plasma kallikrein was measured using 0.09 mM of 
the synthetic substrate H-D-Pro-Phe-Arg-pNA 
(S-2302, Kabi) in 0 .l M sodium phosphate buffer 
(pH 7.6) containing 0.15 M NaCl; 100 1.t1 plasma was 
added to 600 ~1 substrate solution at 37°C and the 
absorbance was recorded at time intervals at 405 nm. 
One amidase unit is equal to 1 I.tmol p-nitroaniline 
released/min [ 181. 
2.5. Activation of plasma kallikrein 
Glass-contact activation of the plasma used for the 
isolation of HM,-BKG was performed in a glass beaker 
left for 24 h at 4°C with gentle magnetic stirring. The 
activity was measured before and after dilution of the 
plasma and was 0.0105 U and 0.0145 U/ml plasma, 
respectively. In the non-glass contact plasma there was 
no activity on H-D-Pro-Phe-Arg-pNA. Total 
activation of plasma prekallikrein in plasma was per- 
formed using 90 J of the plasma sample incubated 
3 min at 37’C with 800 1.t1 1: 10 diluted Cephotest@ 
(Nyegaard, Oslo) in 0.1 M sodium phosphate buffer 
(pH 7.6), 0.15 M NaCl. Substrate was added to give 
the final concentration of 0.09 mM (2 10 ~1) in the 
cuvette and the change of absorbance was recorded 
as before. 
2.6. Radiolabelling of kininogen 
Radiolabelling was performed using the chlora- 
mine T method [ 191 with 10 pg immunoreactive BKG 
dissolved in 25 ,ulO.O5 M sodium phosphate buffer 
(pH 7.5) was iodinated with 1 mCi Na”‘l (New 
England Nuclear, carrier free) diluted in 25 MO.5 M 
buffer. Chloramine T (Merck p.a.) 100 pg in 25 ~1 
0.05 M buffer was added at O’C. After the reaction 
was stopped with 240 c(g sodium metabisulphite 
(BDH) in 100 /.d buffer, Kl (Merck p.a.) 2 mg in 
200 yl buffer was added as carrier. Radiolabelled 
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BKG was separated from free lzsl by gel filtration on 
SephadexG-75 (0.8 cm X 32 cm) with 0.07 M sodium 
diethylbarbiturate (pH 8.6). The column was equili- 
brated with the buffer containing 0.2% gelatine (Sigma, 
G-2500, from swine skin). Radioactivity was measured 
in a Wallac GTL 300-500 gamma sample counter. 
Specific activity was -10-20 pCi/Mg immunoreactive 
BKG. The protein was stored at -20°C 1 :lO diluted 
in 0.05 M sodium phosphate buffer (pH 7.5) contain- 
ing 0.2% gelatine, 0.15 M NaCl and 0.01% NaN3, used 
in all further dilutions. 
2.7. Radioimmunoassay 
Samples of 5-l 00 1.11 SDS-PAGE gel strip eluates 
were analyzed by radioimmunoassay. The RIA was 
performed by incubating 0.2 ml samples or BKG stan- 
dards, 0.1 ml radiolabelled BKG (5000-10 000 cpm) 
with 0.1 ml diluted antiserum calibrated to bind 50% 
of the maximal radioactivity at 4°C for 18 h. Normal 
rabbit serum 5 fl was added as carrier. Antibody 
bound 12’l-BKG was precipitated by adding 0.25 ml 
1: 10 diluted sheep anti-rabbit-IgG [26] and incubated 
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Fig.1. Antibody binding curves obtained using (a) anti-L&f,- 
BKG serum (titer 0.3 mg/ml) dilutions lo-’ to 5 X 10s4 with 
‘*Wabelled LMr-BKG and (b) anti-BKGC serum (titer 1 mg/ 
ml) dilutions 5 X lo-’ to 2 X lo-’ with ‘*‘I-BKGC in the 
radioimmunoassay procedure without unlabelled kininogen as 
inhibitor. The maximal precipitation of ‘251-Iabelled kinin- 
ogen using the highest antibody concentration was (a) 60% 
and (b) 86%; radioimmunoassay standard curves obtained 
using (c) LM,-BKG for inhibition of binding of ‘*sI-LMr-BKG 
(0) and BKGC (0) for inhibition of binding of 1251-labelled 
BKGC to the corresponding antisera, (d) LM,-BKG for inhibi- 
tion of binding of ‘Z”I-Iabelled L&f,-BKG to anti-LM,-BKG 
serum (0) and anti-BKGC serum (0). B/B,, is the ratio of 
radioactivity bound in the presence of Inhibitor and absence 
of inhibitor (assayed in triplicate samples). 
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for 2 h at 22°C with shaking. The precipitate was col- 
lected by centrifugation (5000 X g, 4’C) and counted 
for radioactivity in the gamma sample counter. 
3. Results and discussion 
The antibody binding curves for the antisera gainst 
LMr-BKG and BKG-C are shown in fig.la,b indicating 
that 50% binding was obtained atthe final dilution 
1: 12 800 and 1: 160 000, respectively. The inhibition 
curves of these proteins with their corresponding anti- 
sera (fig.lc) are linear from 5 ng (detection limit) to 
100 ng which illustrates the measuring range applied 
in these studies. When both antisera were tested 
against IMr-BKG parallel dose response curves were 
obtained (fig.1 d). These two antisera were accordingly 
used independently in the present radioimmunoassay 
analyses. Recent approaches for determination of
H.MW and LMW kininogen by RIA report similar sen- 
sitivity of the assay [21,22]. 
Fig2a demonstrates that three variants of HMr 
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Fig.2. Radioimmunoassay of gel strips sliced and eluted after 
SDS-PAGE (8%) runs of molecular variants of H&f, kinin- 
ogen, in (a) 15 ~g immunoreactive kininogen (open) against 
anti-BKGC serum, (b) 20 Irg reduced (shaded) 85 000 HM, 
against anti-LM, serum. The respective stained (Serva blue@) 
gels run in parallel showing the position of the heavy and 
light chains; molecular markers (M,): 78 000,68 000,43 000 
and 12 000 (fromleft to right). The RIA was performed us@ 
the respective kininogen standards. 
kininogen can be shown by RIA eluted with 100 /.d 
TES buffer yielding 27 ng, 76 ng and 70 ng for the 
molecular forms 105 000,90 000 and 86 000, respec- 
tively, per 10 I.tl eluate. In our preparation the 
120 000 Mr form of HMW-BKG was not present appar- 
ently as a consequence of degradation by intrinsic kal- 
likrein activated by glass contact. We estimated the 
degree of activation to -5% of the total kallikrein 
activity 0.290 f 0.037 units/ml on H-D-Pro-Phe- 
Arg-pNA obtained with Cephotest@. After QAE- 
chromatography -10% of the total immunoreactive 
kininogen (9 mg) was collected in the HM, fraction 
pool, which is within the normal distribution range. 
Instead of DFP the PMSF inhibitor was applied in 
. 
‘r 
no BKG 
120 - 
100. 
80 
20 40 80 80 100 
“2 BKG C 
40 
Fig.3. Radioimmunoassay of gel slices after SDS-PAGE runs 
of 15 pg native (open) and reduced (shaded) kininogens: (a) 
HM, kininogen molecular forms (105 000-85 000 M,), seen 
after reduction in the stained gel, RIA against anti-BKG-C 
serum with BKG-C standard; (II) LMr kininogen native 
(58 000 M,) and after reduction against anti-LM$ininogen 
serum with L&f, kininogen standard; (c) reduced BKW kinin- 
ogen against anti-LMr kininogen antiserum. 
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these studies. The degradation of I-Elf, was restricted 
by this inhibitor known to inhibit kallikrein but not 
the activation of prekallikrein. This agrees with [ 151 
where degradation of purified HM, kininogen and kal- 
likrein in vitro and showed that 12 1 000 Mr kininogen 
was converted to an intermediate of 102 000 Mr and 
finally to an end product of 95 000 Mr, using SDS- 
PAGE and coagulation activity. As shown in fig.2,3 
degradation produced still another HM, derivative of 
kininogen with 8.5 000 Mr. Regardless of apparent 
enzymic cleavage these results demonstrate that intrin- 
sic proteinase activation does not affect the antigenic 
determinant in the heavy chain. 
As demonstrated in fig2b with reduced Hiker kinin- 
ogen using the anti-INr kininogen serum only the 
heavy chain responds in RIA. This agrees with [ 1 ] 
where, by immunoelectrophoresis using specifically 
adsorbed antisera, the light chain was suggested to 
contain a unique antigenic determinant that distin- 
guishes Hi& kininogen from IJ!r kininogen. 
The size of the H- and L-chain obtained from these 
molecular HM, forms of kininogen (fig.3a) agree with 
results of -68 000-58 000 Mr and -37 000-48 000 
Mr, respectively, presented by others on SDS-PAGE 
with reduced 110 000- 120 000 HM, kininogen 
[l-3]. The RIA in fig.3a detects only the H-chain 
after reduction depending on the antiserum used. As 
shown in [9] the BKG-C antigen has the characteris- 
tics of the H-chain of IN, and HM, kininogen, veri- 
fied in fig.3c showing only one component after 
reduction of BKG-C, which corresponds in size to the 
H-chain in fig3a. So far there are no available data 
on the L-chain of human IJfr kininogen. With bovine 
mr kininogen it has been reported to have 4800 Mr 
[23]. The apparently same Mr-value obtained on SDS- 
PAGE with IJ4r kininogen before and after reduction 
is so far unexplained (fig.3b) but may depend on the 
carbohydrate structure of the H-chain. As shown in 
[23] no carbohydrate was detectable in the bovine 
Iil4, kininogen L-chain and there is only a slight dif- 
ference in the carbohydrate content of the H-chains 
of bovine HM, and IN, kininogens [24]. Glycopep- 
tides also routinely migrate slower than polypeptides 
of the same Mr-value when subjected to SDS-PAGE 
[25]. Further favourable evidence is the observation 
[26] that IJ!fr kininogen behaved as a 52 000 Mr pro- 
tein in both non-dissociating and dissociating condi- 
tions. This is further strengthened by the considerable 
variation of M,-values reported for human IN, kinin- 
ogen depending on the method [7,8,26,27]. 
244 
We describe a method for the detection of molecu- 
lar variants of human plasma kininogen and verify by 
radioimmunoassay the earlier suggestions [ 1,9,10] 
that the H-chain of HMr and IN, kininogens share 
antigenic determinants also found in the antigen iso- 
lated from Cohn’s plasma fraction IV. 
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